Key Summary Points {#FPar1}
==================

***Why carry out this study?***Multiple sclerosis results in considerable financial burden.Research of costs in highly active multiple sclerosis is scarce, especially in the Finnish setting.Drug-related costs of three multiple sclerosis treatments and a treatment mix of fingolimod and natalizumab in highly active relapsing multiple sclerosis were modelled over 4 years in Finland.***What was learned from the study?***Drug-related costs of cladribine tablets were €71,413 per patient. The respective per-patient costs for fingolimod, natalizumab and treatment mix were €16,424; €58,035; and €24,746 higher, respectively.Cladribine tablets were robustly projected to be a cost-saving treatment option compared to fingolimod, natalizumab and their treatment mix in the Finnish setting.

Introduction {#Sec1}
============

Multiple sclerosis (MS) is an immune-mediated disorder of the central nervous system with a wide heterogeneity in the clinical course. Most patients are classified as having a relapsing--remitting MS (RRMS) \[[@CR1]\], which is further classified as active or highly active, based on the relapse rate and magnetic resonance imaging (MRI) findings \[[@CR2]\]. Approximately 4--14% of all MS patients, depending on the definition used, already have a highly active disease course from the onset \[[@CR3]\]. During the disease trajectory, this subgroup of patients is marked by a rapid accumulation of functional deficits and MRI activity, despite treatment with one or more disease-modifying drugs (DMDs) \[[@CR4]\].

MS is a leading cause of disability in adults, and requires lifelong treatment \[[@CR5], [@CR6]\]. The average time from MS onset to death is 35 years \[[@CR7]\]. There is no cure for MS, but DMDs prevent relapses and delay disease progression \[[@CR8]\].

According to the Finnish treatment guidelines, patients eligible to receive a DMD for highly active disease need to show one relapse in the previous year and at least one T1 gadolinium-enhancing lesion or 9 or more T2 lesions while on therapy with a DMD, or two or more relapses in the previous year, whether or not on DMD \[[@CR9]\]. Three approved DMDs for the highly active disease are used in Finland: cladribine tablets, fingolimod and natalizumab \[[@CR10]--[@CR12]\]. Cladribine tablets are approved for use for the treatment of adult patients with highly active relapsing MS, including RRMS, and relapsing secondary progressive MS populations \[[@CR10]\].

Finland is a high-risk MS region with a prevalence of 280/100,000 in southwest parts of the country \[[@CR13]\], and a nationwide prevalence estimate between 10,000 and 11,000 patients, corresponding to a crude prevalence of 180--200/100,000 \[[@CR14]\]. The estimated annual economic burden of MS in Finland using a bottom--up approach of costing was €46,994 per patient on average and increasing from €10,835 to €109,901 in parallel with advancing disability \[[@CR15]\]. Based on a modelled economic evaluation of RRMS patients who have initiated a DMD, effective and reasonably priced DMDs may compensate for various RRMS-related costs in a 15-year time horizon \[[@CR16]\]. The impact of MS medication costs on overall healthcare systems has been assessed by per-member per-period costs, where MS represents the fourth most expensive therapy class following inflammatory conditions, diabetes and cancer \[[@CR17]\]. In Finland, the estimated proportion of total costs attributable to DMDs is high over 1-year \[[@CR15]\] and moderately high (11--18%, depending on DMD) over 15-year \[[@CR16]\] time horizons among RRMS patients who have initiated DMD and were valid for a publicly reimbursed DMD.

The costs and cost-effectiveness of DMDs indicated for highly active disease in Finland have not previously been published. In foreign settings and modelled comparisons, cladribine tablets have been observed to be dominant (i.e. lower cost and higher effectiveness) in various settings: compared to fingolimod in Spanish patients with highly active relapsing disease \[[@CR18]\], compared to alemtuzumab and natalizumab in English patients with highly active RRMS \[[@CR19]\], and compared to alemtuzumab and fingolimod in patients with highly active RRMS as well as compared to natalizumab in patients with rapidly evolving severe disease in the Dutch setting \[[@CR20]\]. A cost assessment model (CAM) was developed to project the costs of DMDs for highly active disease in Finland.

Methods {#Sec2}
=======

The CAM was developed with the programming language *R* to project drug-related costs of selected highly active MS therapies based on input parameters described below. The CAM approach was developed for easy and safe estimation of costs over time. To ensure the coverage of important features, PICOSTEPS principle \[[@CR16], [@CR21]--[@CR23]\] was applied in the CAM dashboard.

PICOSTEPS (Patients--Intervention--Comparators--Outcomes--Setting--Time--Effects--Perspective--Sensitivity analysis) is a framework for reporting health economic studies. It covers the essential parts of health economic evaluations in their order of importance \[[@CR16], [@CR21], [@CR23]\]; (Table [1](#Tab1){ref-type="table"}). PICOSTEPS has been used in multiple Finnish health economic studies and in a Current Care guideline \[[@CR16], [@CR21], [@CR23]\].Table 1PICOSTEPS applied in the highly active relapsing MS cost assessment model (CAM) inputPICOSTEPS \[[@CR16], [@CR21]--[@CR23]\]DefinitionRespective sourcesP: patientsDisease: highly active relapsing MS\[[@CR9]--[@CR12], [@CR24], [@CR25]\]Feasible MS population in Finland: 280 patientsSales statistics estimate for dynamic populationGender: 72% women\[[@CR16]\]Weight: 86.4 kg male, 72.4 kg female\[[@CR26]\]I: interventionCladribine tablets\[[@CR10]\]C: comparatorsFingolimod and natalizumab, and a treatment mix (80% use fingolimod, 20% use natalizumab)\[[@CR11]\], Finnish clinical practice for natalizumab, sales statistics for the treatment mixO: outcomesExpected annual and cumulative drug-associated costs, cost dispersionRationale: \[[@CR27], [@CR28]\]S: settingModelled specialist care in Finland\[[@CR10]--[@CR12]\]; clinical practiceT: timeFour years drug acquisition costs at June 2019 values, hospital district tariffs at 2019 values, other costs at year 2018 values, no discountingRationale: \[[@CR27], [@CR28]\]E: effectsDrug-associated costs (screening, acquisition, administration, monitoring, adverse events, travelling, productivity)SmPCs \[[@CR10]--[@CR12]\] or clinical practice; see Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}P: perspectiveDrug-related costs (partially societal)Logical assumptionS: sensitivity analysesP: 50% or 90% femaleAssumptionP: average age 36 years\[[@CR16]\]P: age--weight distribution\[[@CR26]\]I: adherence decreases 10% each yearAs above, assumptionC: adherence decreases 10% each yearAssumptionS: no screeningAssumptionT: 3-year resultsAssumptionE: fingolimod use based on clinical practiceFinnish clinical practice (fingolimod)E: natalizumab use based on Tysabri SmPC\[[@CR12]\]E: natalizumab administration based on Finnish price tariffs\[[@CR29], [@CR30]\]E: All cost inputs ±20%AssumptionE: fingolimod used after cladribine tablets (sequential approach)Assumption (risks: \[[@CR31]\])P: direct costs\[[@CR32]\]P: direct costs without travelling costs\[[@CR32]\]P: drug costs alone\[[@CR32]\]

Patients {#Sec3}
--------

The yearly number of Finnish relapsing MS patients with highly active disease, who initiate DMD or switch from another DMD, is estimated to be approximately 280, based on Finnish reimbursement statistics. Based on this estimation, the size of the modelled patient population was chosen to be 280.

Patients were modelled to have cladribine tablets 10 mg (cumulative dose 3.5 mg/kg over 2 years) (intervention), or alternatively (1) fingolimod 0.5 mg, (2) natalizumab 300 mg or (3) a treatment mix consisting of 80% patients using fingolimod and 20% of patients using natalizumab based on the Finnish clinical practice, and their similar patient populations defined in their summaries of product characteristics \[[@CR10]--[@CR12]\] (comparators). Highly active disease patients are defined by clinical or imaging features according to the Finnish treatment guidelines and reimbursement criteria \[[@CR9], [@CR24], [@CR25]\]. Seventy-two percent of patients were women in the model input \[[@CR16]\]. Patients were assumed to stay alive until the end of follow-up (4 years).

The analysis was based on modelling, and the data utilized were obtained from previously conducted studies. The study did not include any new studies with human participants or animals performed by any of the authors. Thus, the study was not registered with any clinical trial database.

Resources and Costs {#Sec4}
-------------------

The primary focus on analytical perspective was on drug-related costs. The perspective was partially societal, considering direct drug-related costs, such as drug acquisition and administration costs, monitoring and adverse events (AEs), as well as indirect drug-related costs such as productivity loss (absenteeism) and travelling costs related to the health care resources used. This perspective considers the direct costs to the same extent as the Finnish medicines agency (Fimea) guidelines on the evaluation of hospital products \[[@CR33]\].

Drug-associated screening, acquisition, administration (also including infusions where relevant), monitoring, AEs, travelling, and productivity costs (Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}) were based on Finnish practices, sources and price tariffs \[[@CR16], [@CR29], [@CR30], [@CR34]--[@CR38]\], and SmPCs \[[@CR10]--[@CR12]\]. Official Finnish list prices of drugs from June 2019 were applied. No treatment pauses or discontinuations were permitted in the base case, but their impact was tested in the sensitivity analyses.Table 2Monitoring and AEs associated with each drug based on their respective summaries of product characteristicsTreatmentCladribineFingolimodNatalizumabCost driverExpenseScreeningYear 1Year 2Year 3Year 4ScreeningYear 1Year 2Year 3Year 4ScreeningYear 1Year 2Year 3Year 4MonitoringElectrocardio-gram (EKG), 6 h1Full blood count, FBC12311111JC virus antibodies122Latent infections11Magnetic resonance imaging (MRI) of head and spine111111111111111Ophtalmologic examination1Transaminases, bilirubin15111Varicella zoster (VZ) antibodies11VZ vaccination0.150.15Test taking123001511110022Adverse eventAbnormal laboratory findings related to liver function^a^0.05550.05550.05550.0555Lymphopenia^b^0.1050.1050.1050.1050.04080.04080.04080.0408^a^\[[@CR39]\]^b^(cladribine tablets) \[[@CR40]\], (fingolimod) \[[@CR39]\]Table 3Unit costs utilized in the analysisCost driverExpenseCost (€)ReferenceDrug acquisitionCladribine 10 mg, 1 tbl2433.69FMT 06/19 \[[@CR34]\]Cladribine 10 mg, 4 tbl9624.82FMT 06/19 \[[@CR34]\]Cladribine 10 mg, 6 tbl14,418.91FMT 06/19 \[[@CR34]\]Fingolimod 0.5 mg 7tbl427.62FMT 06/19 \[[@CR34]\]Fingolimod 0.5 mg 28tbl1612.99FMT 06/19 \[[@CR34]\]Natalizumab 300 mg2250.00FMT 06/19 \[[@CR34]\]Drug administrationNatalizumab NaCl for infusion0.87FMT 06/19 \[[@CR34]\]Natalizumab infusion administration^e^309.82\[[@CR38]\] indexed to 2018 value^a^MonitoringElectrocardiogram (EKG), 6 h^f^587.00\[[@CR30]\]Full blood count, FBC4.60\[[@CR35]\]JC virus antibodies70.00\[[@CR35]\]Latent infections120.53\[[@CR35]\]Magnetic resonance imaging (MRI) of head and spine^e^320.00\[[@CR30]\]Ophthalmologic examination^e^215.60\[[@CR36]\] indexed to 2018 value^a^Transaminases, bilirubin4.00\[[@CR35]\]Varicella zoster (VZ) antibodies20.00\[[@CR35]\]VZ vaccination^d^203.68\[[@CR36]\] indexed to 2018 value^a^/FMT 6/2019 \[[@CR34]\]Test taking^d^5.52\[[@CR37]\] indexed to 2018 value^a^Adverse eventAbnormal laboratory findings related to liver function^d^96.26^b^\[[@CR36]\] indexed to 2018 value^a^, VSSHP \[[@CR35]\]Lymphopenia^d^226.83^c^\[[@CR36]\] indexed to 2018 value^a^, \[[@CR35]\]TravellingPrimary care7.40\[[@CR37]\] indexed to 2018 value^a^Secondary care37.80\[[@CR37]\] indexed to 2018 value^a^Productivity lossPrimary care (1/4 day)64.24\[[@CR42]\] indexed to 2018 value^a^Secondary care (half a day)128.48\[[@CR42]\] indexed to 2018 value^a^Full day256.96\[[@CR42]\] indexed to 2018 value^a^*FMT* Finnish Medicines Tariff^a^Official Statistics of Finland \[[@CR41]\]^b^Blood test, specialist paper consultation, specialist telephone consultation, 5% of patients an additional specialist visit and upper stomach ultrasound^c^Lymphocytes differential count, specialist paper consultation, specialist telephone consultation^d^Productivity loss and travelling cost for this procedure estimated to be ¼ day^e^Productivity loss and travelling cost for this procedure estimated to be ½ day^f^Productivity loss and travelling cost for this procedure estimated to be full day

Cladribine tablets were used according to the Mavenclad SmPC, i.e. two annual treatment courses giving a cumulative dose of 3.5 mg/kg over 2 years and applying 86.4 kg average weight for men and 72.4 kg average weight for women (average adult weight in nationally representative FinTerveys study \[[@CR26]\]). In sensitivity analyses, age and age--weight distributions were applied to inform the dosing of cladribine tablets \[[@CR26]\]. In addition, 24% of cladribine tablets users were assumed to initiate fingolimod on the fourth year, based on the proportion of relapse-free patients (76%) in a CLARITY extension study \[[@CR31]\].

Conservatively (i.e. not benefitting cladribine tablets), fingolimod users collected a 7-tablet pack and 13 28-tablet packs from a community pharmacy during the first year of their treatment, and 13 28-tablet packs annually as per label \[[@CR11]\], which is the most affordable treatment practice for fingolimod. In the sensitivity analysis, 14 28-tablet packs were assumed to be collected from a community pharmacy during the first year based on the Finnish clinical practice. Since cladribine tablets and fingolimod have restricted reimbursements in Finland, and they are used in an outpatient setting \[[@CR24], [@CR25]\], the retail prices of Finnish medicine tariff \[[@CR34]\] excluding value added tax (VAT 10%) were used.

Likewise, natalizumab was conservatively assumed to be administered 12 times per year in a hospital setting based on the Finnish clinical practice and the most affordable treatment practice for natalizumab. In the sensitivity analysis, 14 natalizumab infusions took place during the first year and 13 during subsequent years based on the 28-day dosing interval described in the SmPC \[[@CR12]\]. The official wholesale price was used for hospital-administered natalizumab \[[@CR34]\] and its administration cost was accrued from a Finnish study \[[@CR38]\]. In the sensitivity analyses, two other sources for the administration costs were applied. The administration costs (€934.50 and €373.00) were based on a drug-inclusive administration cost (€2623.00) found in the price tariff of the Hospital District of Pirkanmaa, Finland, \[[@CR29]\] of which the cost of administration was derived from the total cost by subtracting (1) the official wholesale price of natalizumab dose (€2250.00) and (2) the average drug price of natalizumab (€1688.50) found in the price tariff of the hospital district of Uusimaa, Finland \[[@CR30]\].

Statistical significance related to risk assessment can be impacted, for example, by assumed statistical power, accrued sample size and follow-up time. Thus, the AEs for CAM were accounted for by annualizing the AE probabilities \[[@CR43]\] of clinical trials \[[@CR39], [@CR40], [@CR44]\], and by applying an inclusion threshold of ≥4% between the active treatment and placebo in the AE probability \[[@CR16]\].

Finally, analytical perspective can have a considerable impact on the outcomes of health economic evaluation (e.g. \[[@CR16], [@CR21], [@CR45]--[@CR47]\]). In this modelled assessment, productivity costs were based on absenteeism due to drug-associated screening, infusions, monitoring, AEs, and travelling. Absenteeism was valued based on the human capital approach using a Finnish valuation. Sensitivity analyses covered different costing perspectives.

Outcomes {#Sec5}
--------

Primary outcomes included undiscounted modelled annual and cumulative treatment-related costs presented in the overall population of 280 patients and per patient. The cost drivers were defined in year 2018 (unit costs in older than year 2018 values were indexed to the year 2018 real value) and 2019 values. Annual costs were calculated by adding up the cost drivers for each treatment per year, and the cumulative costs by adding up the annual costs and the screening costs for each treatment.

Extensive deterministic sensitivity analyses were conducted for all PICOSTEPS inputs.

Results {#Sec6}
=======

Overall, the intervention (cladribine tablets) were projected to reduce the expected drug associated costs in comparison to the comparators (fingolimod, natalizumab, treatment mix) during the 4-year treatment period and associated screening (Figs. [1](#Fig1){ref-type="fig"}, [2](#Fig2){ref-type="fig"}; Tables [4](#Tab4){ref-type="table"}, [5](#Tab5){ref-type="table"}).Fig. 1Annual acquisition costs per patientFig. 2Drug-associated screening costs, and annual monitoring, administration, AEs, travelling, and productivity costs per patient. S = ScreeningTable 4Drug-associated costs (€) per patientDrugScreeningYear 1Year 2Year 3Year 4SumDifference to cladribineCladribine Adverse event02424242495NA Drug acquisition034,37634,3760068,753NA Monitoring5014613503203201952NA Productivity loss71931164848376NA Travelling4653613939238NA Sum61935,00734,92743043071,413NAFingolimod Adverse event01515151558− 37 Drug acquisition021,39620,96920,96920,96984,30315,550 Monitoring38511753343343342562610 Productivity loss71297707070579203 Travelling4615146464633598 Sum50223,03421,43421,43421,43487,83716,424Natalizumab Adverse event000000− 95 Drug acquisition027,00027,00027,00027,000108,00039,247 Drug administration0372837283728372814,91314,913 Monitoring396320320471471197825 Productivity loss6859059063563525172141 Travelling4549149150650620401803 Sum50932,12932,12932,34032,340129,44858,035Treatment mix Adverse event01212121247− 48 Drug acquisition022,51722,17522,17522,17589,04220,290 Drug administration074674674674629832983 Monitoring38710043313623622445493 Productivity loss71355174183183967591 Travelling46219135138138676439 Sum50424,85323,57323,61523,61596,15924,746Table 5Drug-associated costs (€) in the populationDrugs and cost driversScreeningYear 1Year 2Year 3Year 4SumDifference to cladribineCladribine Adverse event0663766376637663726,548NA Drug acquisition09,625,3849,625,3840019,250,767NA Monitoring140,337129,01698,10289,60089,600546,655NA Productivity loss20,00126,06232,41113,36313,363105,200NA Travelling12,96514,94217,01310,79910,79966,519NA Sum173,3039,802,0419,779,547120,399120,39919,995,689NAFingolimod Adverse event0407440744074407416,295− 10,253 Drug acquisition05,991,0175,871,2845,871,2845,871,28423,604,8684,354,101 Monitoring107,708328,94693,55493,55493,554717,316170,662 Productivity loss20,00183,15319,65719,65719,657162,12556,925 Travelling12,96542,30412,85312,85312,85393,82627,308 Sum140,6746,449,4936,001,4216,001,4216,001,42124,594,4304,598,742Natalizumab Adverse event000000− 26,548 Drug acquisition07,560,0007,560,0007,560,0007,560,00030,240,00010,989,233 Drug administration01,043,9021,043,9021,043,9021,043,9024,175,6074,175,607 Monitoring110,74689,60089,600131,892131,892553,7307075 Productivity loss19,049165,089165,089177,788177,788704,801599,602 Travelling12,654137,578137,578141,721141,721571,252504,733 Sum142,4498,996,1698,996,1699,055,3029,055,30236,245,39016,249,701Treatment mix Adverse event0325932593259325913,036− 13,512 Drug acquisition06,304,8146,209,0276,209,0276,209,02724,931,8945,681,127 Drug administration0208,780208,780208,780208,780835,121835,121 Monitoring108,316281,07792,763101,221101,221684,599137,944 Productivity loss19,81199,54048,74351,28351,283270,660165,460 Travelling12,90361,35937,79838,62638,626189,312122,793 Sum141,0296,958,8286,600,3706,612,1976,612,19726,924,6226,928,934

Annual Costs {#Sec7}
------------

Annual modelled costs during the 4-year treatment period were relatively stable for the comparators, but not for cladribine tablets (Figs. [1](#Fig1){ref-type="fig"}, [2](#Fig2){ref-type="fig"}; Tables [4](#Tab4){ref-type="table"}, [5](#Tab5){ref-type="table"}). Cladribine tablets are acquired in the first 2 years, whereas the comparators are acquired continuously.

The modelled total screening costs of cladribine tablets were €619 per patient and €173,303 in the overall population. The modelled total screening costs of fingolimod, natalizumab, and treatment mix were €502, €509, and €504 per patient and €140,674, €142,449, and €141,029, respectively, in the overall population.

In the first year, the modelled costs of cladribine tablets were €35,007 per patient and €9,802,041 in the population. In comparison, the modelled costs of fingolimod, natalizumab, and the treatment mix were €23,034, €32,129, and €24,853 per patient and €6,449,493, €8,996,169, and €6,958,828 in the overall population, respectively.

The modelled costs in the second year with cladribine tablets were €34,927 per patient and €9,779,547 in the overall population. In comparison, the second-year modelled costs of fingolimod, natalizumab, and the treatment mix were €21,434, €32,129, and €23,573 per patient and €6,001,421, €8,996,169, and €6,600,370 in the overall population, respectively.

During the third and fourth years, the modelled drug-associated costs remained unchanged in both years for each treatment. Because cladribine tablets had no drug-acquisition costs in the third and fourth years, the modelled costs of cladribine tablets plummeted by 99% to €430 per patient and €120,399 in the overall population per year. The modelled costs of fingolimod remained the same as during the second year. Modelled natalizumab costs increased by 0.7% compared to the first and second years and rose to €32,340 per patient and to €9,055,302 in the overall population per year, due to JC virus antibody testing and associated blood sampling, travelling, and productivity loss. The increase of modelled natalizumab costs also increased the total cost of the treatment mix compared to the second year of the treatment period by 0.2% to €23,615 per patient and to €6,612,197 in the overall population per year.

Over the 4-year treatment period, the average modelled annual costs were €17,699 for cladribine tablets, €21,834 for fingolimod, €32,235 for natalizumab and €23,914 for treatment mix. Consequently, cladribine tablets were projected to save 19--45% on the average annual drug-associated costs in comparison to the comparators.

Cumulative Costs {#Sec8}
----------------

During the 4-year treatment period, cladribine tablets were found to have lower costs than the comparators in terms of cumulative modelled costs (Tables [4](#Tab4){ref-type="table"}, [5](#Tab5){ref-type="table"}). The modelled cumulative costs for the 4 years including screening were: cladribine tablets €71,413 per patient and €19,995,689 in the overall population of 280 patients, fingolimod €87,837 per patient and €24,594,430 in the overall population, natalizumab €129,448 per patient and €36,245,390 in the overall population, and treatment mix €96,159 per patient and €26,924,622 in the overall population. The largest difference for the cumulative costs in the overall population compared to cladribine tablets was with natalizumab (€58,035 per patient, €16,249,701 in the overall population; 81% difference in the cumulative costs), the second largest with the treatment mix (€24,746 per patient, €6,928,934 in the overall population; 35% difference), and the smallest difference was with fingolimod (€16,424 per patient, €4,598,742 in the overall population; 23% difference).

Comparison of modelled cost drivers between the treatments demonstrates the comparative affordability of cladribine tablets (Tables [4](#Tab4){ref-type="table"}, [5](#Tab5){ref-type="table"}). The modelled cost of cladribine tablets' drug acquisition, monitoring, productivity loss, and travelling was the most affordable. The modelled cost of AEs with natalizumab was the most affordable. Because cladribine tablets and fingolimod are used orally without administration in the health care setting, only natalizumab and the treatment mix have administration costs. Tables [4](#Tab4){ref-type="table"} and [5](#Tab5){ref-type="table"} show the differences between the treatments per cost driver.

The most important cost drivers were drug-acquisition costs. The drug-acquisition costs represented 96.3%, 96.0%, 83.4% and 92.6% of modelled costs associated with cladribine tablets, fingolimod, natalizumab and treatment mix, respectively.

Sensitivity Analyses {#Sec9}
--------------------

Cladribine tablets remained affordable in the extensive sensitivity analyses (Tables [6](#Tab6){ref-type="table"}, [7](#Tab7){ref-type="table"}) with the 4-year time horizon.Table 6Per-patient results of the sensitivity analyses covering all PICOSTEPS components (€)AnalysisCladribine tabletsFingolimod (difference to cladribine tablets)Natalizumab (difference to cladribine tablets)Treatment mix (difference to cladribine tablets)Base case71,41316,42458,03524,74650% of patients women72,46815,36956,98023,69190% of patients women70,55017,28758,89825,609Age of the population 36 years72,58515,25256,86323,574Patient weight based on Finnish real-life distribution instead of on an average72,06515,77257,38224,094Annual adherence drop 10% after 1st year67,976728043,03514,431No screening costs70,79416,54158,14524,861Time horizon 3 years70,983− 458026,1241561Fingolimod utilization: 14 28-tablet packs during the 1st year, 13 packs thereafter71,41317,60958,03525,694Natalizumab utilization: 14 administrations during the 1st year, 13 administrations thereafter71,41316,42471,25427,390Cost of natalizumab administration €934.5071,41316,42488,02030,743Cost of natalizumab administration €373.0071,41316,42461,06825,353All cost inputs -20%57,13113,13946,42819,797All cost inputs +20%85,69619,70969,64229,69524% of cladribine users assumed to switch to fingolimod on the fourth year76,95910,87952,48919,201Direct costs only71,03716,22155,89324,155Direct costs only, no travelling costs70,80016,12354,09123,717Table 7Per-population results of the sensitivity analysis covering all PICOSTEPS components (€)AnalysisCladribine tabletsFingolimod (difference to cladribine tablets)Natalizumab (difference to cladribine tablets)Treatment mix (difference to cladribine tablets)Base case19,995,6894,598,74216,249,7016,928,93450% of patients women20,291,0044,303,42715,954,3866,633,61990% of patients women19,754,0674,840,36316,491,3227,170,555Age of the population 36 years20,323,7774,270,65415,921,6136,600,845Patient weight based on Finnish real-life distribution20,178,2964,416,13416,067,0936,746,326Annual adherence drop 10% after 1st year19,033,1502,038,51012,049,8984,040,788No screening costs19,822,3864,631,37016,280,5556,961,207Time horizon 3 years19,875,290− 1,282,2807,314,798437,136Fingolimod utilization: 14 28-tablet packs during the 1st year, 13 packs thereafter19,995,6894,930,64516,249,7017,194,456Natalizumab utilization: 14 administrations during the 1st year, 13 administrations thereafter19,995,6894,598,74219,951,0707,669,207Cost of natalizumab administration €934.5019,995,6894,598,74224,645,4608,608,085Cost of natalizumab administration €373.0019,995,6894,598,74217,098,9007,098,773All cost inputs −20%15,996,5513,678,99312,999,7615,543,147All cost inputs +20%23,994,8265,518,49019,499,6418,314,72024% of cladribine users assumed to switch to fingolimod on the fourth year21,548,4333,045,99714,696,9575,376,189Direct costs only19,890,4894,541,81715,650,0996,763,473Direct costs only, no travelling costs19,823,9704,514,50915,145,3666,640,680

The only analysis scenario where cladribine tablets were not the most affordable treatment alternative was the time horizon of 3 years, where fingolimod was €4580 less costly per patient and €1,282,280 less costly in the overall population and compared to cladribine tablets.

Cladribine tablets remained affordable after assuming subsequent treatment with fingolimod in the fourth year for a proportion (24%) of patients. The modelled cost of cladribine tablets was €76,959 per patient and €21,548,433 in the overall population. The savings were €10,879, €52,489, and €19,201 per patient and €3,045,997, €14,696,957, and €5,376,189 in the overall population in comparison to fingolimod, natalizumab, and treatment mix, respectively.

From the perspective of health care payer alone, cladribine tablets' modelled savings were projected to be €16,123, €54,091 and €23,717 per patient and €4,514,509, €15,145,366 and €6,640,680 in the overall population in comparison to fingolimod, natalizumab and treatment mix, respectively.

Discussion {#Sec10}
==========

Our CAM-based modelled study of DMD-associated costs demonstrates that cladribine tablets are a cost-saving treatment alternative for patients with highly active relapsing MS compared to fingolimod and natalizumab in the Finnish setting. The average 4-year modelled cost difference of drug-associated costs was €16,424 per patient compared to fingolimod, €58,035 compared to natalizumab, and €24,746 compared to treatment mix. In the overall population of 280 patients, the respective drug-associated cost differences to cladribine tablets were €4,598,742, €16,249,701, and €6,928,934. The most important cost drivers of modelling were drug-acquisition costs, which accrued 96.3% of the total costs for cladribine tablets, 96.0% for fingolimod, 83.4% for natalizumab, and 92.6% for treatment mix, and drug administration for natalizumab, which was the only intravenous drug in the study.

Cladribine tablets were also cost saving in all sensitivity analyses with a 4-year time horizon, even when assuming a sequential approach. These findings are supported by cost estimates from other settings \[[@CR18]--[@CR20]\]. The only exception was with the 3-year time horizon, in which fingolimod was €4580 less costly per patient and €1,282,280 less costly in the overall population compared to cladribine tablets.

As in all health economic modelling, the results of the present study are subject to uncertainty. Although progressive multifocal leukoencephalopathy (PML) is a severe adverse event associated with natalizumab, and to a lesser extent also with other MS drugs \[[@CR48]\], the treatment-related risk of PML in MS is still very low \[[@CR49]\]. Due to the high uncertainty in the PML incidence data in clinical trials, it was not considered in our analyses. The total cost of natalizumab, therefore, can be an underestimate.

In addition, we did not include MS relapses in the analysis, despite their impact on costs based on Finnish real-world evidence \[[@CR16]\], due to the lack of sufficiently comparable evidence regarding relapse incidence. However, as the cost of relapse is likely to be relatively low (€1316 for events not requiring hospitalization and €5619 for events requiring hospitalization \[[@CR16]\]) compared to the total costs observed in the present study, the impact of relapses as AEs on the results would most likely have been low.

The inclusion of decreased persistence over time resulted in a decrease in the drug-acquisition and administration costs, and the decrease was more profound in drugs that were used for the whole 4 years, i.e. fingolimod and natalizumab. As the present analysis considered only drug-related costs, decreased persistence narrowed the cost gap between cladribine and comparators, although cladribine tablets remained the most affordable.

In addition, persistence does not only affect costs but also the treatment effects, which were outside the scope of this study. Therefore, the interpretation of the effect of persistence on the results does not reflect cost-effectiveness results.

Furthermore, the inclusion of costs related to disease progression (disability) could have had a significant impact on the total costs (see, e.g., \[[@CR16]\]). However, their inclusion would have been complicated and most likely given unreliable results, as there are no direct randomised comparisons between cladribine tablets, fingolimod and natalizumab. However, cladribine tablets have demonstrated a comparable efficacy with other DMDs for highly active disease in recent indirect comparison analyses \[[@CR50]--[@CR52]\]. Thus, speculatively, the inclusion of treatment effects could have even increased the affordability of cladribine tablets.

In systematic reviews, indirect comparisons, health economic analyses and models, systematic reporting is especially important \[[@CR21], [@CR50]\]. PICO is commonly applied in, e.g., evidence synthesis and Finnish current care treatment guidelines. Here, we applied an extended version of PICO (PICOSTEPS) \[[@CR16], [@CR21]\] in order to improve the readability of CAM and these results, and to present the core components of CAM. PICOSTEPS has previously been successfully applied in various health economic evaluations \[[@CR16], [@CR21]--[@CR23], [@CR46], [@CR47], [@CR53]--[@CR56]\], and in real-world data-based predictive cost-effectiveness and cost--benefit assessments of first-line RRMS treatments \[[@CR16]\].

In Finland, the prices of hospital-administered drugs may be confidentially negotiated (tendered) by the hospital, which may lead to lower drug costs paid by the hospital than the official drug price list suggests. On the other hand, this may lead to an underestimation of administration costs. As some hospitals' price tariff lists provide a single cost per administration visit (i.e. including both the administration and the drug), the proportion of administration may be higher than that observed by subtracting the official list price from the total cost of the administration visit.

The present study did not address the effectiveness or cost-effectiveness of the treatments, and nor did it include costs related to effectiveness. This was the main limitation of the study. Therefore, further studies are needed to provide this information, and to gain a more complete understanding of the potential of the different treatments.

Conclusion {#Sec11}
==========

Among patients with highly active relapsing MS, cladribine tablets are projected to robustly save expected drug-associated costs in comparison to fingolimod, natalizumab and their mix in Finland.
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